BLACKROCK SMALLER COMPANIES TRUST plc
All information is at 31 March 2009 and unaudited.
Performance at month end is calculated on a capital only basis
One Three One Three Five
Month Months Year Years Years
Net asset value 1.4% -3.4% -43.5% -39.5% -1.7%
Share price 6.8% 4.1% -40.4% -41.1% 0.5%
HGSC ex Inv Trust + AIM* 4.8% 2.5% -43.7% -49.7% -33.9%
Sources: BlackRock and Datastream
*With effect from 1 September 2007 the Hoare Govett Smaller Companies plus AIM
(ex Investment Companies) Index replaced the FTSE SmallCap Index (ex Investment
Companies) as the Company's benchmark. For three year and five year periods the
above index has been blended to reflect this.
At month end
Net asset value Capital only (debt at par value): 224.81p
Net asset value Capital only (debt at fair value): 219.31p
Net asset value incl Income (debt at par value): 230.73p**
Net asset value incl Income (debt at fair value): 225.24p**
Share price: 189.00p
Discount to Capital only NAV (debt at par value): -15.93%
Discount to Capital only NAV (debt at fair value): -13.82%
Net yield: 2.62%
Total assets: £126.7m^
Gearing: 13.2%
Ordinary shares in issue: 48,494,792^^
**includes net revenue of 5.92p.
^includes current year revenue.
^^excludes 1,498,731 shares held in treasury.
Ten Largest Sector
Weightings % of Total Assets
Support Services 12.3
Software & Computer Services 11.1
Financial Services 11.0
Aerospace & Defence 7.0
Oil & Gas Producers 6.6
Industrial Engineering 6.2
Pharmaceuticals & Biotechnology 4.8
Health Care Equipment & Services 3.9
Industrial Metals & Mining 3.8
Nonlife Insurance 3.7
----
Total 70.4
====
Ten Largest Equity Investments (in alphabetical order)
Company
Aveva Group
Brewin Dolphin Holdings
Chemring Group
Dechra Pharmaceuticals
Emerald Energy
Fidessa Group
Mouchel
Rathbone Brothers
Rotork
Ultra Electronics Holdings
Commenting on the markets, Mike Prentis, representing the Investment Manager
noted:
March was a difficult month with early cyclical recovery stocks outperforming
strongly; these are not the type of stock we typically hold, preferring to
invest in high quality growth stocks. The NAV rose by 1.4% during the month,
well behind the benchmark which rose by 4.8%. The FTSE 100 Index rose by 2.5%
during the month.
Of our underperformance in March, 1.7% was due to sector allocation. Our
significant overweight position in defence stocks cost 0.7% in relative
performance, as the market chose to sell this sector which has performed well
over the last year. Our smaller overweight position in healthcare stocks cost
0.3% and our underweight position in oil & gas producers cost 0.2%.
Stock selection accounted for the majority of underperformance. Core holdings
such as Alternative Networks, Chemring, Mouchel and Connaught all saw their
share prices perform poorly. All continue to trade well, although Alternative
Networks is believed to have seen a little weakness, and Mouchel has failed to
win any of the large contracts it has recently tendered for. All have good
revenue visibility or predictability; we remain happy to hold all on
fundamental grounds. One other contributor to underperformance was a lack of
holding in Venture Production, a large benchmark constituent, which looks
likely to be bid for by Centrica.
On the positive side, in relative terms, the best performers were WSP Group and
ITE. WSP delivered strong 2008 results and management were in fighting form;
cash generation was especially good. ITE shares are very lowly rated, but a
recent AGM statement confirmed trading is in line with expectations and revenue
visibility remains very high.
Our portfolio remains defensively positioned and remains underweight UK
consumer stocks. However, we continue to look for attractively valued, early
cycle recovery stocks with dominant market positions. In this context we bought
0.5% of portfolio positions in 3i Group, Cookson and John Wood Group. We sold
holdings in Beazley, where we had some concerns about its investment portfolio,
Hampson, which is quite highly indebted and does not truly dominate its
markets, and Mitie, which continues to trade well but could suffer as corporate
customers revisit budgets.
As we move into April, recovery stocks are continuing to outperform. We suspect
a lot of this is down to shortclosing of crowded trades. Many of the best
performing stocks in our benchmark index only joined it on 1 January 2009 at
the annual rebalancing, having fallen sharply in 2008, and are not typical
smallcaps. We are reviewing these companies to see which, if any, merit a place
in our portfolio.
Latest information is available by typing www.blackrock.co.uk/its on the
internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV
terminal).
27 March 2009
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.